iCAD to Participate in the LD Micro Conference

Related: Press Release, News

iCAD to Participate in the LD Micro Conference iCAD, Inc. (ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, announces that Company management will participate in the LD Micro Conference being held December 3-5, 2013 at the Luxe Sunset Bel Air Hotel in Los Angeles.

Ken Ferry, President and CEO, will present a corporate overview at 5:00 p.m. Pacific time. A live and archived webcast of the presentation will be available in the Investors section of the Company's website at www.icadmed.com.

About iCAD, Inc.

iCAD is an industry-leading provider of Computer-Aided Detection (CAD) technologies, advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. iCAD offers a comprehensive range of high-performance, upgradeable CAD solutions for mammography and advanced image analysis and workflow solutions for Magnetic Resonance Imaging, for breast and prostate cancers and Computed Tomography for colorectal cancer. iCAD's Xoft System, offers radiation treatment for early-stage breast cancer that can be administered in the form of Intraoperative Radiation Therapy or accelerated partial breast irradiation. The Xoft System is also cleared for the treatment of non-melanoma skin cancer and gynecological cancers. For more information, call 877-iCADnow, or visit www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Company's ability to defend itself in litigation matters, the risks relating to the Company's acquisition of Xoft including, the expected benefits of the acquisition may not be achieved in a timely manner, or at all; the Xoft business operations may not be successfully integrated with iCAD's and iCAD may be unable to achieve the expected synergies, business and strategic objectives following the transaction, the risks of uncertainty of patent protection; the impact of supply and manufacturing constraints or difficulties; product market acceptance; possible technological obsolescence; increased competition; customer concentration; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “will”, “continue”, “anticipate”, “likely”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC's website at http://www.sec.gov.

SOURCE: BUSINESS WIRE




More On: Press Release, News



Comment & Share

Related Links
NextBee Mobile Apps for Customer Engagement Programs Bring Multi Channel TouchpointsNextBee Mobile Apps for Customer Engagement Programs Bring Multi Channel Touchpoints
April 17, 2014
Chegg Acquires Student Deals Platform Campus SpecialChegg Acquires Student Deals Platform Campus Special
April 17, 2014
iCAD Reports Continued Growth in Adoption and Utilization of Its Xoft System to Treat Skin CanceriCAD Reports Continued Growth in Adoption and Utilization of Its Xoft System to Treat Skin Cancer
April 17, 2014
Lumos Networks to Host First Quarter 2014 Earnings Call on May 7th, 2014Lumos Networks to Host First Quarter 2014 Earnings Call on May 7th, 2014
April 17, 2014
Unwired Planet Closes Lenovo Patent License and Purchase TransactionUnwired Planet Closes Lenovo Patent License and Purchase Transaction
April 17, 2014


About Author

Subscribe to Author Alerts

Subscribe for News & Specials